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Abstract
Background: Pre-B-cell colony enhancing factor 1 gene (PBEF1) encodes nicotinamide phosphoribosyltransferase
(NMPRTase), which catalyses the rate limiting step in the salvage pathway of NAD
+ metabolism in mammalian
cells. PBEF1 transcript and protein levels have been shown to be elevated in glioblastoma and a chemical inhibitor
of NMPRTase has been shown to specifically inhibit cancer cells.
Methods: Virtual screening using docking was used to screen a library of more than 13,000 chemical compounds.
A shortlisted set of compounds were tested for their inhibition activity in vitro by an NMPRTase enzyme assay.
Further, the ability of the compounds to inhibit glioma cell proliferation was carried out.
Results: Virtual screening resulted in short listing of 34 possible ligands, of which six were tested experimentally,
using the NMPRTase enzyme inhibition assay and further with the glioma cell viability assays. Of these, two
compounds were found to be significantly efficacious in inhibiting the conversion of nicotinamide to NAD
+, and
out of which, one compound, 3-amino-2-benzyl-7-nitro-4-(2-quinolyl-)-1,2-dihydroisoquinolin-1-one, was found to
inhibit the growth of a PBEF1 over expressing glioma derived cell line U87 as well.
Conclusions: Thus, a novel inhibitor has been identified through a structure based drug discovery approach and is
further supported by experimental evidence.
Background
Gliomas are primary malignant tumors, originating in the
brain, and account for 80% of adult primary brain tumors.
The prognosis for patients with glioblastoma multiforme,
a virulent variety of the disease is rather poor, with a med-
ian survival of less than one year [1]. Several molecular
and biochemical abnormalities such as specific chromoso-
mal aberrations, upregulation of epidermal growth factor
receptor (EGFR), loss of phosphate and tensin homology
(PTEN), have been clearly associated with gliomas. Some
pathways associated with higher grade gliomas are upregu-
lation of PDGFRA (platelet derived growth factor receptor
a), CDK4 (cyclin dependent kinase 4) and down-regula-
tion of retinoblastoma (RB1) [1]. NAD
+ biosynthesis has
been shown to be activated in cancers [2]. NAD
+,i n
addition to its role as a redox cofactor, is also used as a
substrate in several biochemical reactions including
mono- and poly-ADP ribosylation (ART and PARP cata-
lyzed), protein deacetylation and ADP-ribose cyclization
[3]. NMPRTase catalyzes the conversion of free nicotina-
mide to nicotinamide mononucleotide (NMN), which is a
key step in the salvage pathway of NAD
+.E x p r e s s i o nl e v e l s
of NMPRTase (also known as visfatin/Pre B-cell enhan-
cing factor1 (PBEF1)), was found to be upregulated in col-
orectal cancers [4], suggesting that NMPRTase may be
crucial for maintaining cellular NAD
+ levels in tumors.
Microarray analyses of glioma cells (grade II to IV) versus
normal brain glial cells has identified differential expres-
sion of NMPRTase in glioma with 2-5 fold upregulation in
glioma cells, depending on the grade of the tumor
(increased expression of NMPRTase with greater progres-
sion of the disease, Grade IV > Grade III > Grade II) [5].
Observation of increased rates of NAD
+ metabolism in
glioma, suggests that the cancer cells may be critically
dependent upon metabolites produced in the pathway,
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The crystal structures of free NMPRTase, NMPRTase
bound to NMN, and NMPRTase bound to the inhibitor
FK866 [6], have been recently reported. FK866 is a
potent small-molecule inhibitor of human NMPRTase,
and the consequent reduction in NAD
+ levels can cause
apoptosis of tumor cells while having minimal effect on
normal cells [7]. FK866 also turns out to be the only
promising inhibitor known, for the enzyme. The struc-
tures provide a basis for understanding substrate specifi-
city, mechanism of enzyme action, and hence provide a
framework for design of novel NMPRTase inhibitors.
An extremely useful step in the rational design of
inhibitors is to utilize the three dimensional structural
information of the target protein and identify a possible
lead compound from large libraries of compounds. The
most efficient method to do this, of course would be to
carry out virtual screening. In the recent years several
docking algorithms have been developed which are
being used for virtual screening of potential ligands to a
given protein at the three dimensional level [8,9]. We
recently developed a parallel version of a popular dock-
ing algorithm - AutoDock [10] and have implemented
this on an IBM Bluegene supercomputer [11], rendering
the docking approach amenable for high throughput vir-
tual screening. Here we report virtual screening of a
large library of compounds and short listing of six can-
didate molecules that are likely to bind to NMPRTase.
These compounds were subsequently tested experimen-
tally for their ability to (a) inhibit the conversion of
nicotinamide to NAD
+ by NMPRTase and (b) inhibit
efficiently the growth of a PBEF1 over expressing glio-
blastoma derived cell line U87. Based on these studies, a
promising lead compound has been identified.
Methods
Reagents and cell lines
Cancer cell lines U373, U138, LN229, U343, U87, U251
and LN18 (all glioma derived cell lines), SW480 (colon
carcinoma), HaCat (immortalized human keratinocytes)
and HBL100 (immortalized human breast epithelial
cells) cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) respectively with 10% Fetal bovine
serum, penicillin and streptomycin at 37 °C in a humidi-
fied atmosphere with 5% CO2.T h es i xb e s td o c k e d
compounds were purchased from Maybridge, Thermo
Fisher Scientific, UK. C14-Nicotinamide (Specific activ-
ity 55 mCi/mmol) was purchased from American Radio
labeled Chemicals, USA.
Virtual screening
Different steps involved in virtual screening are briefly
described below:
a. Selection of ligand library and preparation of ligands
and protein
Virtual screening was performed to identify possible lead
compounds from the Maybridge HitFinder™ database.
The Maybridge HitFinder™ sets are structural represen-
tatives of large non-redundant chemical libraries. This
collection includes 14,400 compounds that represent the
drug-like diversity of the Maybridge Screening Collection
(~56,000 compounds). All the screening compounds fit
Lipinski guidelines for drug-likeness; partition coefficient,
ClogP ≤ 5, H-bond donors ≤ 5, H-bond acceptors ≤ 10,
molecular weight ≤ 500 [12]. The Maybridge HitFinder™
set was obtained from http://www.maybridge.com. The
ligand files were prepared for docking using Schrodinger
Ligprep software [13]. In addition to the generation of
energy minimized 3D structures, Schrodinger Ligprep
was also used for addition of hydrogens and desalting of
metal ions. The main objective of using LigPrep was to
obtain low energy 3D structures of the set of ligands in
the library, for use in further computational studies.
OPLS_2005 force field was utilized to optimize the geo-
metry and minimize the energy. Force field parameters
were assigned to the ligand atoms using default treatment
for possible tautomers, and ionization at a selected pH
range (7 ± 2 by default), and ring conformations (1 ring
conformer by default).The Ligparse module was used
during Ligprep and the ligands with following properties
were removed from the set: molecular weight less than
200, number of neutral acceptor groups greater than 10
and number of neutral donor groups greater than 5. A
total of 13214 ligands were selected and retained out of
the total 14,400 original ligands.
b. Docking
The co-ordinates of the human NMPRTase (2GVG-
complex with the reaction product nicotinamide mono-
nucleotide; 2GVJ- complex with an inhibitor, n-[4-(1-
benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylpropanamide-
FK866 were obtained from Protein Data Bank (PDB)
[14]. The protein file was prepared for docking by
removal of water molecules, addition of polar hydrogens,
removal of ligand and phosphate groups in active site,
and addition of Kollman charges [15]. The macromole-
cule was treated to be completely rigid for all docking
studies to reduce the extensive computational costs. A
grid box encompassing both the NMN and FK866 sites
(86×60×50; 0.375 Å spacing) was constructed and used
for all the docking runs. Our definition of the site as
input for the docking program encompasses the phos-
phate site completely, since the grid box with dimen-
s i o n s8 0×6 0×5 0p o i n t sw i t had e f a u l ts p a c i n go f
0.375 Å, is sufficiently large to encompass the entire
binding pocket and any nearby minor sites such as that
of the phosphate site. Thus, the search space for gener-
ating ligand map files using Autogrid, is big enough to
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parameter files were prepared for each ligand using the
following parameters: ga_pop_size 150; ga_num_evals
2500000; ga_num_generations 500; ga_run 100 and
rmstol 1.0. The Maybridge HitFinder™ dataset was
docked using the parallel version of AutoDock 3, avail-
able in the laboratory using 256 processors on an IBM
cluster. This process greatly reduced the computational
cost and time involved in virtual screening of the large
dataset (~13214). Clustering was performed based on
the similarity in binding modes and affinities in the run
cycles. The size of the clusters refer to the total number
of conformations of the ligand that bind in the same
orientation within the specified RMSD threshold (1 Å
was used in our study) and binding with the same
energy. Thus, a cluster is defined as a unit of such simi-
lar confirmations. More the number in each cluster bet-
ter is the accuracy and confidence of the predicted pose
of the ligand molecule. The Ligand Protein Contacts
(LPC) [16] was used for obtaining the interactions of
docked ligand atoms with the macromolecule, hydrogen
bonding, van der Waals contacts and the solvent acces-
sible surface area.
c. Short listing of potential leads
The docking log files (.dlg) were parsed using in-house
perl scripts to scan the clustering histograms, and iden-
tify ligands that have docked poses with binding energy
lower than the cut-off criteria and cluster size greater
than the defined cut-off (See Table 1). The cut-off
values were obtained from docking the known inhibitor
FK866, and product NMN, to the receptor, and retriev-
ing the docking energy and cluster size values for poses
that have least deviation from the crystal pose (RMSD <
1.0). As a newer version of AutoDock became available
during the course of this work, the docking exercise was
repeated for the short listed compounds with the same
parameters using AutoDock4 (version 4.0.1).
Energy minimization
Minimization of the docked ligands in the best ranked
poses was done using CNS software suite [17]. Conju-
gate gradient method was used for minimization with
flexibility allowed only for those atoms within the 6 Å
radius of every atom of the ligand for 150 runs. The
topology and parameter files for the compounds were
obtained from XPLO-2D software [18]. Molecular
visualization tool Pymol [19] was used to generate the
images of the docked complexes.
RNA isolation and RT-qPCR
RNA isolation and RT-qPCR were carried out as
described before [5]. Total RNA was extracted from
cancer cell lines by using the TRI reagent (Sigma). The
RNA samples were quantified by measuring the absor-
bance using a spectrophotometer and visualized on a
MOPS formaldehyde gel for quality assurance. The rela-
tive quantification of the expression levels of selected
genes was carried out using a two-step strategy: In the
first step, cDNA was generated from RNA derived from
different tissue samples using a cDNA archive kit (ABI
PRISM); subsequently, real-time quantitative PCR was
carried out in an ABI PRISM 7900 (Applied Biosystems)
sequence detection system with the cDNA as template
using PBEF1 specific primer set and a Dynamo kit con-
taining SYBR green dye (Finnzymes). All measurements
were made in triplicates. The genes GARS (glycyl-tRNA
synthetase), AGPAT1 (1-acylglycerol-3-phosphate O-
acyltransferase 1), ATP5G1 [ATP synthase, H
+ trans-
porting, mitochondrial F0 complex, subunit C1 (subunit
9)], and RPL35A (ribosomal protein L35a) were used as
internal controls because their expression levels were
found to be unaltered in microarray experiments. The
fold change (log2 ratio) in PBEF1 gene expression was
calculated over its mean expression in normal brain
samples obtained from previously published results [5].
Delta-delta CT method was used for the calculation of
ratios. Sequences of reverse transcription-PCR primers
and conditions used will be provided on request.
Western blot analysis
Western blot analysis was performed as described pre-
viously [5] with rabbit polyclonal antibody against GST-
PBEF1 raised in the laboratory using a standard immu-
nization protocol and antitubulin antibody.
NMPRTase assay
The measurement of NMPRTase activity was carried out
as described before [7]. To prepare cytoplasmic extract,
as source of NMPRTase, we collected logarithmically
growing U87 glioblastoma cells by centrifugation and
washed three times with Ca
2+ Mg
2+ free PBS. The cells
pellet (2-3 × 10
7 cells) was suspended and lysed in 1 mL
of 0.01 M NaH2PO4 (pH 7.4) by one round of freezing
and slow thawing. The clear supernatant was recovered
on ice after centrifugation at 23,000 × g at 0°C for 90
minutes. 70 mL of 1% protamine sulfate was added per
ml of supernatant and incubated for 15 min on ice, fol-
lowed by centrifugation at 23,000 × g at 0°C for 30 min-
utes. The final supernatant was stored in small aliquots
at -80°C. The NMPRTase activity was determined in 0.5
Table 1 Docking results of control compounds
Biochemical energy of
binding (kcal/mol)
AD4 docked
(kcal/mol)
RMSD from
crystal pose
Size of
cluster
NMN - -8.02 0.87 35
FK866 -9.25 -8.63 0.77 16
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2 mM ATP, 0.5 mM phosphoribosyl PPI, 0.1 mM
14[C]-nicotinamide (specific activity: 50 mCi/mmol;
American Radio labeled Chemicals, Inc.) and 50 mM
Tris (pH 8.8) at 37°C. The reaction was started by add-
ing 100 μL of cell extract and stopped after 1 hr with
excess of cold nicotinamide and heating (2 min, 105°C).
The precipitate was removed by centrifugation at 2500
× g at 4°C for 10 min and the supernatant was stored at
-20°C. The 14[C]-labeled components in the cell
extracts were separated and identified using thin-layer
chromatography (cellulose/1 M ammonium sulphate:
ethanol (3:7)). The chromatograms were run, exposed to
imaging plates (Fuji) and read using Phosphorimager
(Fuji). The 14[C]-labeled NAD
+ was quantified using
Alpha Innotec software.
MTT assay
MTT assay was carried out as described previously [20].
A total of 1.5 × 10
3 cells/well were plated in a 96-well
plate. After 24 h of plating, the cells were treated with
indicated amounts of compounds. A measure of 20 μL
(5 mg/mL) of MTT was added to each well 48 hrs after
the addition of the compounds. MTT is a tetrazolium
salt that is converted by living cells into purple forma-
zan crystals. The medium was removed from the wells
3 hrs after MTT addition and 200 μLo fD M S Ow a s
added to dissolve the formazan crystals, and then the
absorbance was measured at 550 nm in an ELISA
reader.
Results
Description of the binding site
The crystal structures of NMPRTase, in complex with
the known inhibitor FK866, and reaction product NMN,
reveal that the active enzyme exists as a dimer. The
structures of the two complexes were very similar to
each other and no significant conformational changes
were observed upon ligand binding [6], making it mean-
ingful to compare the binding modes of the two ligands.
The catalytic centre is present at the interface of the
two chains. There are two active sites per dimer and
residues from both the chains are involved in the inter-
actions with the product NMN at each site [6]. The
binding pockets of the two ligands overlap partly with
each other, together extending into a single large pocket
resembling a long tunnel, with NMN binding at one
end and FK866 spanning till the other end. Some resi-
dues are common to both, indicating the overlap in
their binding poses. An essential feature of both the
binding poses is the presence of hydrophobic stacking in
which an aromatic group in the ligand is sandwiched
between F193 of one subunit and Y18 of another subu-
nit. The conservation of these interactions, especially
the hydrophobic stacking, was used as a criterion for fil-
tering docked ligands, subsequent to the selection on
the basis of binding energy and cluster size. The unique-
ness of the binding site has been studied by comparing
NMPRTase with closely related NAPRT and QPRT
enzymes, present in the same biochemical pathway
[6]. A multiple sequence alignment of the human
NMPRTase with the other two proteins showed that
they have diverged in terms of sequences considerably,
but adopt the same fold. Yet, analysis of their binding
sites using PocketMatch [21], indicates that considerable
difference exists at the binding site level, suggesting that
design of specific inhibitors can be achieved. It has also
been reported earlier that FK866, a potent inhibitor of
NMPRTase does not inhibit NAPRT, consistent with
this observation [6].
Identification and analysis of potential compounds
As a control study, the enzyme’s reaction product NMN
as well as the known inhibitor, FK866 were docked to
the protein, an exercise which resulted in reproducing
the crystal structure poses for both compounds. Table 1
lists the interaction energies computed for the docked
NMN and FK866 as well as the deviations from the
crystallographic observed poses. The energy values com-
puted for these reference compounds were used as
reference values for identifying possible ligands from the
large compound library. All those compounds which
exhibited interaction energies above this threshold or in
other words indicated binding weaker than the reference
compounds were eliminated from the list for further
analysis. The result of the virtual screening of the data-
set is summarized in Table 2.
For selection of potential ligands, analysis of ligand
protein contacts for top ranking poses of every ligand
was carried out and the interactions of docked com-
pounds were visualized. Interactions conserved with
NMN and FK866 binding were calculated and compared
with that of the short listed compounds. The best poses
were identified using the following criteria in the given
order of preference i) lowest binding energy in the lar-
gest sized cluster ii) number of hydrogen bonds with the
active site residues and iii) conservation of interactions
with those from NMN/FK866 binding. Preference is
given to the largest sized least binding energy cluster
and then examined to verify if one or more hydrogen
bonds are conserved between the natural substrate
NMN, or the previously known inhibitor FK866. This
was to ensure that the ligands shortlisted were actually
docking into the binding site of interest. All the 34
shortlisted from an initial list of 13214 compounds pass
these criteria and is shown in Table 2. The top six in
this list that were readily purchasable were considered
for further studies which are shown in Table 3. The
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docked poses passing the defined thresholds were found
to cluster into two main groups, corresponding to the
binding modes of NMN and FK866 respectively, with
docking energies nearly comparable between the modes
for each ligand. The binding sites for both possible
modes are shown in Figure 1 and Additional file 1,
Figure S1, whereas the list of interactions at the site for
both possible modes are indicated in Table 3, and illu-
strated in Figure 1. 2D-structures of the six compounds
and the two control compounds, FK866 and NMN are
shown in Figure 2.
Inhibition of NMPRTase activity by selected lead
compounds
We then tested whether the selected lead compounds
could inhibit NMPRTase activity. We measured the abil-
ity of NMPRTase to convert 14[C]-nicotinamide to 14
[C]-NAD
+. We had earlier shown that most of the glio-
blastoma tissues have elevated levels of transcript
and protein of PBEF1/NMPRTase [5]. To prepare
NMPRTase enzyme, we first tested a panel of glioma
derived cell lines for NMPRTase transcript and protein
levels. We found that, out of seven glioma cell lines
tested, two cell lines, U87 and U138, had substantially
high levels of PBEF1 transcripts in comparison to nor-
mal brain samples (Figure 3A). Western blotting analysis
also corroborated above results that U87 and U138 had
relatively higher levels of PBEF1/NMPRTase protein
levels (Figure 3B).
Table 2 Virtual Screening results
#ligands Energy
cut-off
# ligands
above
cut-off
Cluster
size cut-
off
Potential
ligands
Maybridge
HitFinder™
13214 < -8.5
kcal/
mol
34 > 15 6
Summary of docking results; (1) Docking of reference compounds to
NMPRTase reproducing the crystal poses; (2) An overview of results of virtual
screening to the same protein molecule.
Table 3 Binding Free Energy for the six identified compounds and the control compounds
Comp
no.
Compound name Binding Free
energy (kcal/
mol)
Number
in clusters
Residues in the binding pockets
1 Dipotassium 9-oxo-9H-fluorene-2,7-
disulfonate
-8.56
(Mode I)
54 F193, R196,G 197, R311, G353,V 356,G 384, Y18
1,T 391
1, R392
1, D393
1
-7.98
(Mode II)
32 Y188,H 191,F 193,D 219,V 242,A 244, A245,S 275,I 309, R311,I 351,Y 18
1
2 Ethyl-5-amino-6-cyano-7-(2-furyl)-4-oxo-3-
phenyl-3,4-dihydro-1-phthalazinecarboxylate
-9.45
(Mode I)
44 F193, R196,D 219,E 246, H247,R 311, D313,G 353, D354,G 355,V 356,
G381,S 382,G 383,G 384,G 385, D16
1,Y 18
1,E 149
1, K415
1, K423
1
-8.12
(Mode II)
14 Y188, H191,G 217,Y 240,S 241,V 242,P 273,P 307,I 309, R349,V 350,
I351,I 378,A 379,Q 92
1
3 1,[3,5-Di(2H-1,2,3-benzotriazol-2-yl)-2,4-
dihydroxyphenyl]ethan-1-one
-9.55
(Mode I)
18 F193,R 196, R311, G353,D 354,G 355,V 356,G 381,S 382, G383,G 385,
D16
1,Y 18
1,R 40
1, R392
1,D 393
1,N 396
1
-8.69
(Mode II)
15 Y188,K 189, H191,F 193,G 217, D219,Y 240,S 241,V 242,A 244,S 275,
I309,R 311,R 349,V 350,I 351,E 376,N 377,I 378,A 379,Y 18
1
4 7a-methyl-2,4,5-triphenyl-7,7a-
dihydrocyclopenta[b]pyran-7-one
-8.56
(Mode I)
40 F193, R196,H 247, G353,D 354,G 355,V 356,G 381,S 382,G 383,G 384,
G385, Y18
1,R 40
1, R392
1,S 398
1,K 415
1,K 423
1
-8.23
(Mode II)
27 Y188,K 189, H191,Y 240,S 241,V 242,P 307,I 309,R 349,V 350,E 376,I 378,A 379
5 3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-1,2-
dihydroisoquinolin-1-one
-10.54
(Mode I)
38 F193, R196,D 219,A 244, H247, R311, D313, G353,D 354, G355,V 356,
Y18
1,E 149
1,R 392
1, S398
1,F 399
1, K415
1,K 423
1
-9.84
(Mode II)
16 G185, Y188,K 189, H191,Y 240, S241, V242,S 275,I 309,R 349,I 351,
E376,A 379
6 N-[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)
methyl]-2H-chromene-3-carboxamide
-9.86
(Mode I)
16 F193, R196, D219,V 242,A 244,S 275,G 353,D 354,G 355,V 356,G 381,
S382,G 383, G384,G 385, D16
1,Y 18
1
-9.64
(Mode II)
10 Y188, H191,F 193,D 219, Y240,S 241,V 242,A 244, S275,I 309,I 351,
Y18
1,H 90
1,Q 92
1
7 CONTROL -8.63 16 F193,G 194,Y 195, R196,G 197,D 219, R311,D 313,G 353, V356,G 384, G385
n-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-
3-ylpropanamide (FK866)
D16
1,Y 18
1, R392
1,D 393
1
8 CONTROL -8.02 27 F193, R196, G353,D 354,G 355, V356, D357, G381,S 382,G 383, G384,
G385, K389, R392
1,D 393
1
Nicotinamide ribose monophosphate (NMN)
Binding energy for six compounds and control compounds NMN, and FK866 along with residues in each site. The subscript refers to the residue number.
Residues involved in hydrogen bond interactions are shown in boldface.
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Figure 1 Crystal poses of the Control compounds and docked poses of the identified compounds. Crystallographically observed binding
modes of the known and new ligands in NMPRTase; (a) NMN, (b) FK866, and docked binding modes of compounds 4 and 5. (c) and (e) panels
indicate the first binding modes of compounds 5 and 4 respectively while panels (d) and (f) indicate the second binding modes of compounds
5 and 4 respectively. The ligands are in ball and stick representation and colored by standard atom types; the A chain residues of the site are
shown in red and C chain residues are in blue, in all the panels.
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NMPRTase enzyme extract from U87 converted the 14
[C] labeled nicotinamide to NAD
+ ( F i g u r e3 Cl a n e1 ) .
FK866, the known inhibitor of NMPRTase inhibited this
reaction efficiently (Figure 3C compare lane 2 with 1).
As expected, the extract from U251 cells, which had
very low levels of PBEF1 transcript and protein, did not
convert 14[C] labeled nicotinamide to NAD
+ (Figure 3C
lane 3). We then tested the ability of six selected lead
compounds to inhibit NMPRTase activity. We found
that, of the six compounds tested, compounds 4 and 5
inhibited NMPRTase activity (Figure 4A and 4B) signifi-
cantly. Compound 5 was found to be more potent in
NMPRTase inhibition (Figure 4A and 4B compare lanes
23-26 with lanes 1 and 2).
Inhibition of growth PBEF1 over expressing glioblastoma
cell line U87
To correlate the NMPRTase inhibition property with cell
growth inhibition, we then tested the ability of these
compounds to inhibit the growth of a glioma derived cell
line U87, which has elevated levels of PBEF1. FK866, the
known NMPRTase inhibitor, inhibited the growth of U87
cells efficiently with an IC50 of 170 μM( F i g u r e5a n d
Table 4). Of the six selected lead compounds, we found
that only compounds 1 and 5 inhibited the growth of U87
cells with an IC50 of 335 and 325 μM respectively (Figure
5 and Table 4). Since compound 1 did not inhibit
NMPRTase activity (Figure 4), it might utilize a different
mechanism to inhibit the growth of U87 cells. However,
compound 5 inhibited NMPRTase activity as well as the
growth of U87 cells. Further to confirm that inhibition of
U87 cell growth by FK866 and compound 5 is because of
their ability to inhibit NMPRTase, we tested the effect of
these two compounds on the growth U251 cells which
does not express NMPRTase. As expected, neither FK866
nor compound 5 inhibited U251 cells, while adriamycin
inhibited very efficiently (data not shown). We thus con-
clude that compound 5 is a potent inhibitor of NMPRTase
and cancer cell growth.
1) 2) 3)
4) 5) 6)
7) 8)
Figure 2 2D- structures of compounds. 2D-structures of the six compounds along with the control compounds FK866 and NMN; panels
numbered 1 to 6 indicate the 2D-structures for compounds 1-6, and panels numbered 7 and 8- for FK866 and NMN respectively.
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Virtual screening procedure carried out resulted in
short-listing of six compounds which were obtained and
tested experimentally using both the enzyme inhibition
assay as well as the cell growth inhibition assay. It is
indeed gratifying that two of the six compounds clearly
exhibit enzyme inhibition. This clearly demonstrates the
usefulness of the docking based virtual screening
approach used here, utilizing three dimensional struc-
tural information at atomic level detail.
Analysis of the docked poses indicate that two bind-
ing modes are observed within the large tunnel like
binding pocket encompassing sites for both the natural
product NMN and the partly overlapping larger inhibi-
tor FK866. Given that the docking algorithm uses
heuristics, a typical docking simulation is carried out
by repeating each run about 150 times, each time
using a different random number as a seed. This clus-
tering pattern obtained subsequently for each docking
simulation reflects the propensity of the ligand to
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Page 8 of 12occupy the binding site in the respective modes. Figure
S1a-S1f shows the binding sites of all the six com-
pounds. For all the six compounds tested, distinct clus-
ters were observed indicating the two modes of
binding as top ranking poses, the first overlapping in
position with that of the natural product NMN and
the second overlapping substantially with that of
FK866. Figure S1i shows the superposition of the site
of FK866 (as in 2GVJ) and the site corresponding to
the second binding mode of compound 5, which
clearly illustrates that the identified compound 5 occu-
pies the same pocket as that of FK866.
The interactions observed in the first mode include a
stacking interaction of the aromatic ring in the ligand
w i t ht h es i d ec h a i n so fF 1 9 3o fo n es u b u n i ta n dY 1 8o f
another subunit. In the second mode, interactions with
Y188, K189, Y240, S241, V242, S275, I309, R349, I351,
and E376 are commonly seen. Figure 1 shows the bind-
ing sites of both modes for compound 4, 5; single
modes of NMN (as in 2GVG) and FK866 (as in 2GVJ).
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are conserved in the NMPRTase proteins from several
sources and their close sequence homologues.
Interestingly, Compound 5 docked with the lowest
binding energy of all the compounds in both modes. It
forms more number of hydrogen bonds with the binding
site residues, all of them being crucial for NMN/FK866
binding. The two modes reflect the most plausible
modes of binding for the compounds studied, and any
one of them may be more important than the other
for achieving inhibition. Irrespective of that, compound
5i ss e e nt ob eab e t t e rl i g a n di nb o t ht h ep o s e s ,
further corroborated by the experimental studies. To
Figure 5 Glioma cell growth inhibitor screen. Viability was measured by MTT assay at 48 hrs after addition indicated compounds to U87 cells.
The assays were carried out in triplicates and the mean value for each time point was used to generate the graph.
Table 4 IC50 values for the compounds
Compound Name IC50 (μM)
FK866 170
Niacin > 500
Nicotinamide > 500
Compound 1 335
Compound 2 > 500
Compound 3 > 500
Compound 4 > 500
Compound 5 325
Compound 6 > 500
List of compounds and their IC50 values.
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high in cellular environment, and hence the possibility of
high population of NMPRTase molecules bound to NMN
and subsequently any influence this might have for bind-
ing compound 5, we repeated the docking exercise with
NMPRTase bound to product NMN and next with natural
substrate nicotinamide. The second mode of binding for
compound 5 was reproduced in this exercise, indicating
that this compound will be capable of binding to the
enzyme in the presence of NMN/nicotinamide also and
will not have to compete with NMN/nicotinamide. This
observation leads to favoring the second mode binding as
being more important for achieving inhibition. Competi-
tion assays using enzyme kinetics has been carried out for
FK866, but the interpretation of whether it is a competi-
tive or non-competitive inhibitor is not clear [4,5]. It may
also be possible that the compounds could inhibit the
enzyme by both modes of action, thus exhibiting a ‘mixed
inhibition’. Despite these, the fact remains that both
FK866 and the new compound identified in this study are
effective in inhibiting glioma cell growth and this has been
demonstrated to be mediated via inhibition of NMPRTase.
The compound 5 also exhibited highest efficacy in
enzyme inhibition and in cell growth assay among all
the compounds tested. This compound had, in addition
to the hydrophobic and aromatic interactions, hydrogen
bonding interactions with F193, G353, G384, R196,
H247 and R311 of one subunit and Y18 of another sub-
unit in the first mode; and Y188 and H191 in the sec-
ond mode. The other compounds, though bind at the
same location do not have hydrogen bonding moieties
in them, perhaps explaining higher strength of binding
and hence inhibition by compound 5.
Conclusion
Virtual screening by molecular docking, carried out using
AutoDock, has thus proved to be useful in short listing
potential lead compounds. Recently Colombano and cowor-
kers [22] reported the synthesis of FK866 analogues and
showed that two of them were indeed good inhibitors of
NMPRTase. All these are however based on the same scaf-
fold. It is indeed useful to see that two new molecules
belonging to different scaffolds have now been identified
and tested through experimental methods. Compound 5 in
particular, serves as a promising lead compound for further-
ing structure based discovery of drugs for use in glioma.
Additional material
Additional file 1: Figure S1 Binding site of the six identified
compounds and the two control compounds. Figure showing the
binding sites of all the top six compounds along with the control
compounds, NMN and FK866.
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